NV 5138
Alternative Names: NV-5138; SPN 820; SPN-820/821; SPN-821Latest Information Update: 20 May 2025
At a glance
- Originator Navitor Pharmaceuticals; X-Chem
- Developer Navitor Pharmaceuticals; Supernus Pharmaceuticals
- Class Antidepressants; Pentanoic acids; Small molecules
- Mechanism of Action MTORC1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Depressive disorders; Major depressive disorder
Most Recent Events
- 06 May 2025 Supernus Pharmaceuticals plans a phase IIb trial for Major depressive disorder
- 04 Mar 2025 Efficacy and adverse event data form the phase IIb trial in Depressive disorders was released by Supernus
- 15 Feb 2025 Navitor Pharmaceuticals completes a phase II trial in Depressive disorders (Treatment-resistant) in USA (PO) (NCT05066672)